Research and analysis

ACMD advice on acyl piperazine opioids, including 2-methyl-AP-237

This report has considered the harms and control of 2-methyl-AP-237 and other closely related acyl piperazine opioids.

• From: Advisory Council on the Misuse of Drugs
• Published: 27 March 2024

Documents

ACMD advice on acyl piperazine opioids, including 2-methyl-AP-237 (accessible)

HTML

ACMD advice on acyl piperazine opioids, including 2-methyl-AP-237

PDF, 490 KB, 38 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Cover letter from ACMD with advice on acyl piperazine opioids, including 2-methyl-AP-237 (accessible)

HTML

Cover letter from ACMD with advice on acyl piperazine opioids, including 2-methyl-AP-237

PDF, 182 KB, 6 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Following the 66th session of the United Nations Commission on Narcotic Drugs, 2- methyl-AP-237 was added to the relevant Schedule 1 of the Single Convention on Narcotic Drugs of 1961.

On 19 June 2023, the government commissioned the Advisory Council on the Misuse of Drugs (ACMD) to review the harms and consider control of 2-methyl-AP-237, to comply with our international obligations.

The ACMD has, therefore, written this report which considers the harms and control of 2-methyl-AP-237 and other closely related acyl piperazine opioids.

The report also provides recommendations on classification and scheduling following a thorough review of the evidence available.

We are aware that this publication may have accessibility issues. We are reviewing it so that we can fix these.

Read more about our accessible documents policy.

Published 27 March 2024